KRAS mutations impact clinical outcome in metastatic non-small cell lung cancer
Ella A. Eklund, Clotilde Wiel, Henrik Fagman, Levent M. Akyürek, Sukanya Raghavan, Jan Nyman, Andreas Hallqvist, Volkan I. Sayin
doi: https://doi.org/10.1101/2021.11.27.21266822
Ella A. Eklund
1Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden
2Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden
3Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
Clotilde Wiel
1Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden
2Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden
Henrik Fagman
4Department of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden
5Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden
Levent M. Akyürek
4Department of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden
5Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden
Sukanya Raghavan
6Department of Microbiology and Immunology, Institute for Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Jan Nyman
3Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
7Department of Oncology, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden
Andreas Hallqvist
3Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
7Department of Oncology, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden
Volkan I. Sayin
1Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden
2Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Posted February 14, 2022.
KRAS mutations impact clinical outcome in metastatic non-small cell lung cancer
Ella A. Eklund, Clotilde Wiel, Henrik Fagman, Levent M. Akyürek, Sukanya Raghavan, Jan Nyman, Andreas Hallqvist, Volkan I. Sayin
medRxiv 2021.11.27.21266822; doi: https://doi.org/10.1101/2021.11.27.21266822
Subject Area
Subject Areas
- Addiction Medicine (347)
- Allergy and Immunology (666)
- Anesthesia (181)
- Cardiovascular Medicine (2637)
- Dermatology (223)
- Emergency Medicine (398)
- Epidemiology (12211)
- Forensic Medicine (10)
- Gastroenterology (758)
- Genetic and Genomic Medicine (4087)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2646)
- Health Policy (1003)
- Hematology (362)
- HIV/AIDS (850)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (433)
- Neurology (3862)
- Nursing (209)
- Nutrition (577)
- Oncology (2022)
- Ophthalmology (584)
- Orthopedics (240)
- Otolaryngology (304)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (472)
- Pediatrics (1113)
- Primary Care Research (450)
- Public and Global Health (6516)
- Radiology and Imaging (1398)
- Respiratory Medicine (871)
- Rheumatology (404)
- Sports Medicine (342)
- Surgery (444)
- Toxicology (52)
- Transplantation (185)
- Urology (165)